Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BMS-986205

- PMLiVE

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma

- PMLiVE

BMS finds a new immunotherapy partner with $12m Compugen deal

Combination with novel antibody targeting PVRIG pathway

Bristol Myers Squibb logo

BMS psoriasis drug hits the mark in phase II

Tyrosine kinase 2 (Tyk2) inhibitors could play major role

- PMLiVE

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

Becomes the first checkpoint inhibitor for this indication

Bristol-Myers Squibb (BMS) building

BMS presses go on Nektar combo pivotal trials, despite data debate

The data isn’t mature enough to give an accurate ORR reading, says companies

- PMLiVE

Immuno-oncology at ASCO: survival data, combinations and new indications

The abstracts reveal heaps of strong contenders in the NSCLC category

- PMLiVE

Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more

A rapid round-up of pharma, biotech and healthcare news

Bristol-Myers Squibb (BMS) building

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

- PMLiVE

FDA panel undermines Lilly and Incyte’s baricitinib hopes

Mixed review doesn’t bode well in competitive market

Bristol-Myers Squibb (BMS) building

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Data shows the combo can improve survival compared to Pfizer’s Sutent

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links